Altimmune Stock (NASDAQ:ALT)
Previous Close
$7.15
52W Range
$2.48 - $14.84
50D Avg
$7.04
200D Avg
$7.62
Market Cap
$531.30M
Avg Vol (3M)
$2.67M
Beta
0.07
Div Yield
-
ALT Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| AVXL | Anavex Life Sciences Corp. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| VSTM | Verastem, Inc. |
| FBIO | Fortress Biotech, Inc. |
| ARDX | Ardelyx, Inc. |
| AVRO | AVROBIO, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| VKTX | Viking Therapeutics, Inc. |
| CABA | Cabaletta Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ATHA | Athira Pharma, Inc. |
| BIVI | BioVie Inc. |
| SAVA | Cassava Sciences, Inc. |
| CGTX | Cognition Therapeutics, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| INMB | INmune Bio, Inc. |
| ZURA | Zura Bio Limited |
| MDGL | Madrigal Pharmaceuticals, Inc. |